Japan Diabetes Society Requires Actos Information Sharing
This article was originally published in PharmAsia News
Executive Summary
Following France's Actos (pioglitazone) restrictions on treatment-naïve diabetes patients, the Japan Diabetes Society sent a request for information sharing on the drug's adverse effects